Trial Update November 9, 2026

Cetrorelix Phase 3 Trial NCT05326087 Listed as Not Yet Recruiting

A Phase 3 clinical trial involving cetrorelix was updated on November 9, 2026, with a status of not yet recruiting. The study, registered as NCT05326087, is titled "Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A." The trial is designed to compare two protocols, progestin primed ovarian stimulation (PPOS) and GnRH antagonist protocol, in women with polycystic ovary syndrome (PCOS) who are undergoing preimplantation genetic testing for aneuploidy (PGT-A). Cetrorelix, a GnRH antagonist, is an approved compound relevant to this antagonist protocol arm of the study. As the trial has not yet begun recruiting participants, no enrollment, results, or outcome data are currently available. The listing reflects only the trial's registration status and design as recorded on ClinicalTrials.gov. No efficacy or safety conclusions can be drawn from this update. Readers interested in the compound can consult the cetrorelix overview for additional background and context on its approved uses.

See the full cetrorelix overview

Source: https://clinicaltrials.gov/study/NCT05326087